Segment Reporting - Segment information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Segment Reporting
Grant revenue	$ 491	$ 966
Total research and development expenses	5,429	8,016
Total general and administrative expenses	3,253	3,178
Total operating expenses	8,682	11,194
Operating loss	(8,191)	(10,228)
Other income (expense), net	1,660	(14,793)
Net loss	(6,531)	(25,021)
Single Reportable Segment
Segment Reporting
Grant revenue	491	966
Expenses not allocated by projects	520	632
Total external research and development expenses	744	2,653
Research and development personnel expenses	2,313	2,613
Other research and development expenses	2,372	2,750
Total research and development expenses	5,429	8,016
General and administrative personnel expenses	1,401	934
Other general and administrative expenses	1,852	2,244
Total general and administrative expenses	3,253	3,178
Total operating expenses	8,682	11,194
Operating loss	(8,191)	(10,228)
Other income (expense), net	1,660	(14,793)
Net loss	(6,531)	(25,021)
Single Reportable Segment | AP-PA02: Non-Cystic Fibrosis Bronchiectasis
Segment Reporting
External research and development expenses	(440)	1,834
Single Reportable Segment | AP-PA02: Cystic Fibrosis
Segment Reporting
External research and development expenses	11	97
Single Reportable Segment | AP-SA02: Bacteremia
Segment Reporting
External research and development expenses	652	83
Single Reportable Segment | AP-SA02Prosthetic Joint Infection
Segment Reporting
External research and development expenses	$ 1	$ 7